Wednesday, January 17, 2018
Disruptive technologies come in many forms. Sometimes the disruption comes in the form of new technologies or, in other cases, it can be a new business model. However, in each situation the disruption causes incumbents to lose market share. In...
As we enter the new year it is very difficult not to be optimistic...borderline exuberant. The Tailwinds Select Portfolio has been on a tear lately, closing the year with a bang. If gaining 20% in the last two months...
TORONTO, Nov. 27, 2017 (GLOBE NEWSWIRE) -- 3D Signatures Inc. (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0) (the "Company" or "3DS") is pleased to announce its intention to raise $1.5 million CAD by way of a non-brokered private placement of 7,500,000 units (the...
Tailwinds' Take: Once funded, expect the good news to roll for 3DS. This company has a unique technology with many opportunities to partner on developing products. We recently doubled our weighting at this deal price and think the placement...
Tailwinds' Take: the first good news for 3DS in a while comes shortly after the arrival of a strategic investor into the Company. Hidden at the end of this release is a patent for Alzheimers as well. 3DS has...
Tailwinds' Take: this is a key endorsement as the Company looks to lock up more financing. Once they are funded, there should be a nice pathway towards clinical success in the not too distant future. TORONTO, Oct. 03, 2017 (GLOBE...
3D Signatures has been trying to raise money for months. To date, they have not been successful. I think that will change soon as there is too much value here to be ignored. Meanwhile, the fact that the management...
TORONTO, ON (June 8, 2017) − 3D Signatures Inc. (TSXV:DXD; OTCQB:TDSGF; FSE:3D0) (the "Company" or "3DS"), is pleased to announce that the clinical trial component (the “Clinical Trial”) of its Hodgkin’s lymphoma (“HL”) test (“Telo-HL”) validation program is successfully...
Tailwinds' Take: 3DS accomplished a lot this last quarter, but the bigger catalysts should be coming in the second half of this year as the company advances on several fronts. TORONTO, May 31, 2017 (GLOBE NEWSWIRE) -- 3D Signatures Inc. (TSXV:DXD)...
Tailwinds Take: a well written article by David Templeton of the Pittsburgh Post-Gazette that discusses the work of Dr. Sabine Mai in conjunction with Dr. Hans Knecht on the use of telomeres in cancer diagnostics. Discovery, the goal of science,...
Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address